PRECISION OPTICS CORPORATION, INC.
POCIDrugs in Pipeline
22
Phase 3 Programs
6
Upcoming Catalysts
6
Next Catalyst
Jun 15, 2026
8wMarket Overview
Stock performance and key metrics
6 upcoming, 1 past
PRAX-562
SCN2A Encephalopathy
PRAX-114
Major Depressive Disorder
1mg elsunersen
Epileptic Encephalopathy
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Focal Seizure
1.0mg/kg/day PRAX-562
Developmental and Epileptic Encephalopathy 1
40 mg/day vormatrogine for 12 weeks
Focal Epilepsy
CEA-targeted CAR-T cells
Gastric Cancer
ICT-107
Glioblastoma Multiforme
PDI-192
Atopic Dermatitis
NEO-201 in combination with pembrolizumab
Non Small Cell Lung Cancer
10 mg PRAX-114
Major Depressive Disorder
CD123 targeted CAR-NK cells
Acute Myeloid Leukemia
100 mg PRAX-944
Essential Tremor
BCMA targeted prime CAR-T cells
Multiple Myeloma
CD19 and CD22 targeted prime CAR-T cells
B-ALL
30mg PRAX-628
Focal Onset Seizure
BCMA CAR-T cells
Multiple Myeloma
NPC-1C/NEO-102
Metastatic Pancreatic Cancer
Part A: 20 and 40 mg PRAX-944
Essential Tremor
pCAR-19B cells
Acute Lymphoblastic Leukemia
donor-derived NK cell infusion
Non-small Cell Lung Cancer
PRAX-222 - Initial Dose
SCN2A-DEE
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRAX-562 | Phase 3 | SCN2A Encephalopathy | - | - |
PRAX-114 | Phase 3 | Major Depressive Disorder | - | - |
1mg elsunersen | Phase 3 | Epileptic Encephalopathy | - | - |
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks | Phase 3 | Focal Seizure | - | - |
1.0mg/kg/day PRAX-562 | Phase 3 | Developmental and Epileptic Encephalopathy 1 | - | - |
40 mg/day vormatrogine for 12 weeks | Phase 3 | Focal Epilepsy | - | - |
CEA-targeted CAR-T cells | Phase 2 | Gastric Cancer | - | - |
ICT-107 | Phase 2 | Glioblastoma Multiforme | - | - |
PDI-192 | Phase 2 | Atopic Dermatitis | - | - |
NEO-201 in combination with pembrolizumab | Phase 2 | Non Small Cell Lung Cancer | - | - |
10 mg PRAX-114 | Phase 2 | Major Depressive Disorder | - | - |
CD123 targeted CAR-NK cells | Phase 2 | Acute Myeloid Leukemia | - | - |
100 mg PRAX-944 | Phase 2 | Essential Tremor | - | - |
BCMA targeted prime CAR-T cells | Phase 2 | Multiple Myeloma | - | - |
CD19 and CD22 targeted prime CAR-T cells | Phase 2 | B-ALL | - | - |
30mg PRAX-628 | Phase 2 | Focal Onset Seizure | - | - |
BCMA CAR-T cells | Phase 2 | Multiple Myeloma | - | - |
NPC-1C/NEO-102 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
Part A: 20 and 40 mg PRAX-944 | Phase 2 | Essential Tremor | - | - |
pCAR-19B cells | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
donor-derived NK cell infusion | Phase 2 | Non-small Cell Lung Cancer | - | - |
PRAX-222 - Initial Dose | Phase 2 | SCN2A-DEE | - | - |